Latest in Finance

Malvern Panalytical acquires Dimer Instruments to expand biopharma analysis

The purchase strengthens Malvern Panalytical’s biopharmaceutical characterisation capabilities, building on the development of its high-throughput Zetasizer Core stability screening platform

Find out more
Malvern Panalytical acquires Dimer Instruments to expand biopharma analysis

Corsearch launches AI-powered pharmaceutical naming platform

Corsearch launches AI-powered pharmaceutical naming platform

Corsearch Pharma combines AI-driven name generation, trademark screening and regulatory risk assessment in a single workflow to help pharmaceutical companies accelerate drug...
See more
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network

The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Bayer invests $2.2bn in new US pharmaceutical manufacturing site

Bayer invests $2.2bn in new US pharmaceutical manufacturing site

Bayer will build a new modular pharmaceutical manufacturing campus in New Albany, Ohio, with drug substance production expected to begin in 2031
Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager

Novartis signs deal worth up to $7.8bn for Abogen’s mRNA T-cell engager

The Swiss pharma company has agreed to pay $575m upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager targeting B-cell-driven autoimmune diseases
SK pharmteco commits $200m to US small molecule and peptide manufacturing expansion

SK pharmteco commits $200m to US small molecule and peptide manufacturing expansion

The five-year investment adds GMP kilo-scale peptide purification, new development laboratories and upgraded manufacturing suites — creating 100 high-skilled roles as the CDMO strengthens domestic API supply chain resilience alongside its existing Ireland and South Korea expansions
You need to be a subscriber to read this article.
Click here to find out more.
BioNTech closes four sites after failed sale process as post-COVID vaccine sales slump

BioNTech closes four sites after failed sale process as post-COVID vaccine sales slump

The closure of three German facilities and the Singapore plant should free up to €500m annually, redirecting capital into BioNTech's late-stage oncology pipeline as the company pivots away from pandemic-era mRNA vaccine manufacturing
Roche signs $2bn Atavistik Bio deal for allosteric drug discovery

Roche signs $2bn Atavistik Bio deal for allosteric drug discovery

Roche and Atavistik Bio will use the biotech’s AMPS platform to discover oral small-molecule treatments for cardiovascular, renal and metabolic diseases
You need to be a subscriber to read this article.
Click here to find out more.
Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup

Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup

From a £10m isotope refinery raise to Copeland's Dickson acquisition and a $14m DARPA-backed red blood cell programme, here is this week's biggest pharma manufacturing and life sciences funding news
From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

By integrating GEA granulation technology into its new facility, Beta Pharmacon has enhanced process control, reinforced its commitment to regulatory compliance, and secured GMP and USP qualifications to supply essential micronutrient supplements

Latest posts in Finance

GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

The company has agreed to acquire a potential best-in-class trispecific T-cell engager with the aim of developing and commercialising it for multiple myeloma, with Phase I trials expected in 2027
OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

OutSee will use Innovate UK and Empirical Ventures funding to develop an agentic AI sub-system designed to accelerate initial validation of drug targets identified by its predictive genomics platform, Nomaly
Onyx Scientific invests £1.5m into Sunderland API plant

Onyx Scientific invests £1.5m into Sunderland API plant

The expansion brings the site to ten GMP suites by Q1 2027, increasing concurrent capacity for commercial API production and accelerating early-phase programmes — as well as creating nine immediate roles in production chemistry, analytical and QA
PerkinElmer acquires SimoTech to expand pharma manufacturing automation

PerkinElmer acquires SimoTech to expand pharma manufacturing automation

The acquisition strengthens PerkinElmer’s pharmaceutical services offering with SimoTech’s expertise in manufacturing automation, digital manufacturing and GMP IT systems
Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

The agreement gives Novartis options to develop and commercialise multiple subcutaneous products using Alteogen’s ALT-B4 hyaluronidase technology
Lilly to acquire Merida Biosciences for up to $2.875bn

Lilly to acquire Merida Biosciences for up to $2.875bn

Eli Lilly is acquiring Merida Biosciences in a deal worth up to $2.875bn to expand its pipeline of precision therapies for autoimmune and allergic diseases
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Prescient completes integration of Uptake and Dolon under single global brand

Prescient completes integration of Uptake and Dolon under single global brand

Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging has acquired pharmaceutical packaging specialist Paperpack, expanding its European network and strengthening its presence in South-Eastern Europe
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows

Sponsor Promoted Content

Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the...
SPI Pharma and Colorcon announce strategic global partnership

SPI Pharma and Colorcon announce strategic global partnership

Partnership combines complementary expertise to help pharmaceutical formulators address complex solid oral dose development challenges
Gerresheimer successfully completes sale of Centor

Gerresheimer successfully completes sale of Centor

Proceeds will be used to lower Gerresheimer’s debt
Gerresheimer reports stronger Q2 as adjusted EBITDA rises more than 50%

Gerresheimer reports stronger Q2 as adjusted EBITDA rises more than 50%

Drug delivery demand supports second-quarter growth as Gerresheimer prepares for a stronger second half
Grand opening ceremony for IMA Life North America in Tonawanda, USA

Grand opening ceremony for IMA Life North America in Tonawanda, USA

The new facility covers an area of 120,000 square feet and supports the company’s production of state-of-the-art pharmaceutical equipment, producing life-saving patient...
Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Long-term agreement extends manufacturing commitments through 2033 and takes cumulative contract value beyond USD 21.9 billion
Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Preliminary results: Revenues of 524 million EUR, adjusted EBITDA of 66 million EUR; stronger second half of the year expected
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

Significant optimisation of the capital and financing structure through expected cash inflows, meaningfully decreasing leverage
LogiPharma Digital Supply Chain Connect announces 2026 agenda for pharma supply chain summit

LogiPharma Digital Supply Chain Connect announces 2026 agenda for pharma supply chain summit

Exclusive Frankfurt event to bring together senior pharma supply chain leaders, digital transformation specialists and technology partners
Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza grants Engitix target-specific license for GlycoConnect, HydraSpace and SYNtecan E linker-payload technologies for ADC development
Gerresheimer publishes 2025 annual and consolidated financial statements

Gerresheimer publishes 2025 annual and consolidated financial statements

Stable revenue in a challenging financial year